Relay Therapeutics RLAY
$16.12 +$0.21 (+1.32%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $16.19 +0.46%
Open$15.59
Prev close$15.91
Day range$15.17 – $16.33
Volume3.98M
Market cap$3.56B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$90.25M-12.3% YoY
Net profit-$81.75M-10.2% YoY
Diluted EPS-$0.37+14.0% YoY
Free cash flow-$63.93M-2.9% YoY
Operating cash flow-$63.93M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-3,094.6%
Net margin-2,837.0%
Return on equity-41.2%
Return on assets-37.4%
Return on invested capital-43.1%
Current ratio14.62
Liabilities / assets9.2%
Cash & investments$848.64M
Total debt$23.54M
Net cash (debt)$825.10M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $0.00 | $350,000.00 | $3.00M | $15.36M | $7.00M |
| Total Operating Revenue | $0.00 | $350,000.00 | $3.00M | $15.36M | $7.00M |
| Operating Expense | $90.25M | $91.17M | $81.59M | $318.09M | $67.63M |
| Selling and Admin Expenses | $13.11M | $14.69M | $11.03M | $56.71M | $12.22M |
| -General & Admin Expense | $13.11M | $14.69M | $11.03M | $56.71M | $12.22M |
| Research & Development | $77.14M | $76.48M | $70.56M | $261.38M | $55.42M |
| Operating Profit | -$90.25M | -$90.82M | -$78.59M | -$302.74M | -$60.63M |
| Net Non-Operating Interest Income (Expense) | $8.50M | $7.12M | $5.35M | $27.04M | $5.71M |
| Non-Operating Interest Income | $8.50M | $7.12M | $5.35M | $27.04M | $5.71M |
| Other Income (Expense) | -$2,000.00 | $2,000.00 | -$53,000.00 | -$776,000.00 | $30,000.00 |
| Other Non-Operating Income (Expenses) | -$2,000.00 | $2,000.00 | -$53,000.00 | -$776,000.00 | $30,000.00 |
| Pretax Profit | -$81.75M | -$83.71M | -$73.29M | -$276.48M | -$54.89M |
| Net Profit | -$81.75M | -$83.71M | -$73.29M | -$276.48M | -$54.89M |
| Profit from Continuing Operations | -$81.75M | -$83.71M | -$73.29M | -$276.48M | -$54.89M |
| Net Income to Parent Company | -$81.75M | -$83.71M | -$73.29M | -$276.48M | -$54.89M |
| Net Income to Common Stockholders | -$81.75M | -$83.71M | -$73.29M | -$276.48M | -$54.89M |
| Basic EPS | -$0.37 | -$0.41 | -$0.41 | -$1.61 | -$0.32 |
| Diluted EPS | -$0.37 | -$0.41 | -$0.41 | -$1.61 | -$0.32 |
| Special Income (Charges) | – | – | – | $0.00 | $0.00 |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $901.69M | $967.46M | $699.61M | $621.33M | $621.33M |
| Total Current Assets | $864.85M | $928.08M | $658.46M | $578.28M | $578.28M |
| Cash and Cash Equivalents & Short-Term Investments | $848.64M | $910.93M | $642.07M | $554.52M | $554.52M |
| -Cash and Cash Equivalents | $124.18M | $121.19M | $204.59M | $84.02M | $84.02M |
| -Short Term Investments | $724.46M | $789.75M | $437.48M | $470.50M | $470.50M |
| Prepaid Assets | $8.68M | $8.74M | $11.84M | $17.79M | $17.79M |
| Other Current Assets | $7.53M | $8.41M | $4.56M | $5.97M | $5.97M |
| Total Non-Current Assets | $36.84M | $39.38M | $41.15M | $43.05M | $43.05M |
| Net PPE | $30.90M | $38.04M | $39.82M | $41.72M | $41.72M |
| -Gross PPE | $30.90M | $38.04M | $39.82M | $63.26M | $63.26M |
| Goodwill and Other Intangible Assets | $4.75M | – | – | $0.00 | $0.00 |
| Other Non-Current Assets | $1.20M | $1.34M | $1.34M | $1.34M | $1.34M |
| Total Liabilities | $82.70M | $77.45M | $57.43M | $54.27M | $54.27M |
| Total Current Liabilities | $59.15M | $50.80M | $29.75M | $25.58M | $25.58M |
| Payables | $9.19M | $11.46M | $4.10M | $7.71M | $7.71M |
| -Accounts Payable | $9.19M | $11.46M | $4.10M | $7.71M | $7.71M |
| Current Accrued Expenses | $45.06M | $34.08M | $20.91M | $13.65M | $13.65M |
| Short-Term Debt and Capital Lease Obligation | $3.49M | $4.01M | $3.89M | $3.77M | $3.77M |
| -Current Capital Lease Obligation | $3.49M | $4.01M | $3.89M | $3.77M | $3.77M |
| Other Current Liabilities | $1.42M | $1.25M | $847,000.00 | $463,000.00 | $463,000.00 |
| Total Non-Current Liabilities | $23.54M | $26.64M | $27.68M | $28.69M | $28.69M |
| Long Term Debt and Capital Lease Obligation | $23.54M | $26.64M | $27.68M | $28.69M | $28.69M |
| -Long Term Capital Lease Obligation | $23.54M | $26.64M | $27.68M | $28.69M | $28.69M |
| Total Equity | $819.00M | $890.01M | $642.18M | $567.06M | $567.06M |
| Stockholders' Equity | $819.00M | $890.01M | $642.18M | $567.06M | $567.06M |
| Capital Stock | $212,000.00 | $211,000.00 | $182,000.00 | $168,000.00 | $168,000.00 |
| -Common Stock | $212,000.00 | $211,000.00 | $182,000.00 | $168,000.00 | $168,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $3.08B | $3.06B | $2.73B | $2.58B | $2.58B |
| Retained Earnings | -$2.25B | -$2.17B | -$2.09B | -$2.01B | -$2.01B |
| Gains/Losses Not Affecting Retained Earnings | -$5.36M | -$1.55M | -$172,000.00 | $733,000.00 | $733,000.00 |
| -Accumulated Depreciation | – | – | – | -$21.55M | -$21.55M |
| Current Deferred Liabilities | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$63.93M | -$54.11M | -$51.11M | -$235.46M | -$44.87M |
| Net cash flow from continuing operations | -$63.93M | -$54.11M | -$51.11M | -$235.46M | -$44.87M |
| Net Income from Continuing Operations | -$81.75M | -$83.71M | -$73.29M | -$276.48M | -$54.89M |
| Depreciation & Depletion & Amortization | $280,000.00 | $360,000.00 | $504,000.00 | $3.56M | $599,000.00 |
| Change in Working Capital | $5.32M | $20.68M | $11.92M | -$23.31M | -$2.82M |
| -Change in Prepaid Assets | $940,000.00 | -$751,000.00 | $7.36M | $1.61M | $3.82M |
| -Change in Payables and Accrued Expense | $3.95M | $20.52M | $3.67M | -$11.44M | -$6.53M |
| -Change in Other Current Liabilities | $172,000.00 | $405,000.00 | $384,000.00 | -$1.53M | -$615,000.00 |
| -Change In Other Working Capital | $250,000.00 | $507,000.00 | $506,000.00 | -$11.95M | $508,000.00 |
| Net cash flow from investing | $62.37M | -$353.03M | $32.90M | $192.80M | $35.46M |
| Net Cash Flow from Continuing Investing Activities | $62.37M | -$353.03M | $32.90M | $192.80M | $35.46M |
| Net PPE Purchase and Sale | $0.00 | $0.00 | $0.00 | -$410,000.00 | -$1,000.00 |
| Net Investment Purchase and Sale | $62.37M | -$353.03M | $32.90M | $193.21M | $35.46M |
| Financing Cash Flow | $4.42M | $323.74M | $138.78M | $1.60M | $934,000.00 |
| Net Cash Flow from Continuing Financing Activities | $4.42M | $323.74M | $138.78M | $1.60M | $934,000.00 |
| Net Common Stock Issuance | $0.00 | $318.94M | $137.09M | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $4.42M | $4.79M | $1.69M | $1.60M | $934,000.00 |
| Ending Cash Balance | $125.38M | $122.53M | $205.93M | $85.35M | $85.35M |
| Net Change in Cash | $2.86M | -$83.40M | $120.57M | -$41.05M | -$8.47M |
| Beginning Cash Balance | $122.53M | $205.93M | $85.35M | $126.41M | $93.82M |
| Free Cash Flow | -$63.93M | -$54.11M | -$51.11M | -$235.87M | -$44.87M |
| Gain/Loss from Continuing Operations | – | – | – | $1.00M | $35,000.00 |
| -Change in Receivables | – | – | – | $0.00 | – |
No comments yet — be the first to weigh in on RLAY.
Sign in to join the discussion.